Skip to main content
TipRanks
Go Ultimate75% OFF

ACADIA Pharmaceuticals (0A4W) AI Stock Analysis

0 Followers
GB:0A4W

ACADIA Pharmaceuticals

(LSE:0A4W)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
DAYBUE growth and expansionDAYBUE is showing strong volume-led growth, with expanding adoption across community practices and centers of excellence. European approval, planned Japan submission, and STIX restarts broaden the addressable opportunity and support a durable multi-year commercial growth trajectory.
Negative Factors
Weaker recent free cash flowThe recent decline in free cash flow indicates that accounting profitability is not converting into cash as effectively as in 2024 and 2025. If this persists, it could reduce internally generated funding for pipeline investment and make earnings quality less dependable over the next several quarters.

ACADIA Pharmaceuticals (0A4W) vs. iShares MSCI United Kingdom ETF (EWC)

0%10%20%30%40%50%GB:0A4W+44.31%EWC+15.06%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$3.08B
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
8.4
Beta (1Y)
0.09
Revenue Growth
14.82%
EPS Growth
36.49%
Country
UK
Employees
797
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

ACADIA Pharmaceuticals Business Overview & Revenue Model

Company Description

Acadia Pharmaceuticals Inc. operates as a biopharmaceutical company, primarily dedicated to discovering, developing, and commercializing small molecule therapeutics. Their core focus lies in addressing critical unmet medical needs within the realm of...

ACADIA Pharmaceuticals Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:0.00%|Next Earnings Date:Mar 01, 2027
Earnings Call SentimentPositive

The call conveyed strongly positive commercial momentum, with record DAYBUE sales, substantial STIX adoption, European approval, extended patent protection, continued NUPLAZID growth, and a strong cash position. The pipeline outlook was constructive, supported by a clear 60-milligram remlifanserin efficacy signal, favorable safety findings, and multiple development programs, although the RADIANT primary endpoint narrowly missed statistical significance and the company is managing a leadership transition and timing-related NUPLAZID guidance constraints. Highlights significantly outweighed the lowlights.

Positive Updates

Strong Third-Quarter Revenue Growth
Total revenues were $342 million in the third quarter, representing 22% year-over-year growth on an adjusted basis.

Negative Updates

RADIANT Primary Endpoint Missed Statistical Significance
The Phase II portion of the RADIANT study in Alzheimer's disease psychosis narrowly missed statistical significance on the primary SAPS H+D endpoint, with a p-value of 0.0603.

Company Guidance

Acadia now expects total revenues of $1.265 billion to $1.295 billion for 2026, DAYBUE full year global net sales of $505 million to $520 million, NUPLAZID full year net sales of $760 million to $775 million, DAYBUE gross-to-net of approximately 23% to 24%, NUPLAZID gross-to-net of approximately 22% to 23%, R&D expenses of $325 million to $340 million, and SG&A expenses of $665 million to $685 million; it remains confident in reaching $700 million in DAYBUE sales by the end of 2028 and approximately $1 billion in NUPLAZID net sales by the end of 2028, expects Phase II results from ILLUMERA in the fourth quarter of 2027, an additional NORLIGHT data readout in the second half of 2027, an expected 2027 regulatory submission for DAYBUE in Japan, and a targeted launch in 2028.

ACADIA Pharmaceuticals Risk Analysis

ACADIA Pharmaceuticals disclosed 55 risk factors in its most recent earnings report. ACADIA Pharmaceuticals reported the most risks in the "Legal & Regulatory" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Legal & Regulatory - Litigation, compliance, new legislation, and taxation risks

Latest Risks Added

0 New Risks

ACADIA Pharmaceuticals Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

GB:0A4W against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
HRMYHRMY77Outperform$1.94B10.7518.55%―19.79%-4.89%
PTCTPTCT64Neutral$5.03B-45.9857.10%―-35.05%-113.73%
BHVNBHVN59Neutral$1.95B-3.34-2271.87%――49.16%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
IMMXIMMX51Neutral$603.45M-8.57-24.93%――-5.65%
XENEXENE46Neutral$3.71B-8.03-39.80%―-100.00%-21.09%

* Healthcare Sector Average

Performance Comparison

0%100%200%GB:0A4WPTCTXENEHRMYIMMXBHVNDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
GB:0A4W and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
GB:0A4WACADIA Pharmaceuticals Inc.26.878.2544.31%
PTCTPTC Therapeutics60.23-18.24-23.24%
XENEXenon Pharmaceuticals37.75-3.41-8.28%
HRMYHarmony Biosciences Holdings, Inc.33.11-1.20-3.50%
IMMXImmix Biopharma, Inc.7.112.7864.20%
BHVNBiohaven Ltd.12.903.2133.13%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.